Analysis of the efficacy and safety of naloxegol administered to patients with cancer and opioid-induced constipation with laxative-inadequate response: A real-world 12 months of follow-up study.
Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Begoña Soler, Pedro Sánchez Mauriño(Hospital Universitario Reina Sofía), Alexandra Giraldo(Vall d'Hebron Hospital Universitari), Alfredo Paredes Lario(Biogipuzkoa Health Research Institute), Gala Serrano Bermúdez(Ajuntament de L’Hospitalet), Ignacio Delgado(Universitat Autònoma de Barcelona), Oliver Higuera(Hospital Universitario La Paz), Almudena Sanz-Yagüe, Ibone Huerta-González, Luis Cabezón‐Gutiérrez(Hospital Universitario de Torrejón), Antonio Javier Jiménez-López, Rodolfo Chicas-Sett(Hospital Universitario de Gran Canaria Doctor Negrín), José-Luis Fírvida Pérez(Complejo Hospitalario de Ourense), Francisco Javier García Navalón(Hospital Son Llatzer), Anna Librán-Oriol, Pilar Togores(Centro Oncológico de Galicia), Carmen Beato(Hospital Universitario Virgen Macarena), Diana Moreno(Hospital Universitario Fundación Alcorcón), Isabel Blancas(Instituto de Investigación Biosanitaria de Granada)
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2024|291
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
|Journal of Clinical Oncology|2024|211
Differential Abilities of SNAP-25 Homologs to Support Neuronal Function
|Journal of Neuroscience|2007|144